# EDGAR Filing Document

**Accession Number:** 0001728117
**File Stem:** 0001728117-26-000028
**Filing Date:** 2026-4
**Character Count:** 2804
**Document Hash:** b05d3ca6093bdf97c937ed98be941add
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001728117-26-000028.hdr.sgml**: 20260424

**ACCESSION NUMBER**: 0001728117-26-000028

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260424

**DATE AS OF CHANGE**: 20260424

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Gossamer Bio, Inc.
- **CENTRAL INDEX KEY:** 0001728117
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475461709
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38796
- **FILM NUMBER:** 26893468

**BUSINESS ADDRESS:**
- **STREET 1:** 3115 MERRYFIELD ROW
- **STREET 2:** SUITE 120
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 684-1300

**MAIL ADDRESS:**
- **STREET 1:** 3115 MERRYFIELD ROW
- **STREET 2:** SUITE 120
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14A** 

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

**(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;)** 

Filed by the Registrant ⌧&nbsp;&nbsp;&nbsp;&nbsp;Filed by a Party other than the Registrant ◻

Check the appropriate box:

◻Preliminary Proxy Statement

◻&nbsp;&nbsp;&nbsp;&nbsp;Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

◻&nbsp;&nbsp;&nbsp;&nbsp;Definitive Proxy Statement

⌧&nbsp;&nbsp;&nbsp;&nbsp;Definitive Additional Materials

◻&nbsp;&nbsp;&nbsp;&nbsp;Soliciting Material under §240.14a-12

**Gossamer Bio, Inc.** 

**(Name of Registrant as Specified In Its Charter)** 

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** 

Payment of Filing Fee (Check the appropriate box):

---

| | |
|:---|:---|
| ⌧ | No fee required. |
| ◻ | Fee paid previously with preliminary materials. |
| ◻ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 with preliminary |

---

ote "FOR" Proposal 2. 2. Ratification of the appointment of Ernst & Young LLP as our independent registered public accountants for the year ending December 31, 2020. TO ATTEND the Annual Meeting of Gossamer Bio, Inc., please visit www.proxydocs.com/GOSS for virtual meeting registration details. The control number located in the shaded gray box will be required to register. INTERNET www.investorelections.com/GOSS TELEPHONE (866) 648-8133 \*E-MAIL paper@investorelections.com ACCOUNT NO. &nbsp;&nbsp;&nbsp;&nbsp;SHARE

------

![notice1-defa14axpage1.jpg](notice1-defa14axpage1.jpg)

------

![notice2-defa14axpage2.jpg](notice2-defa14axpage2.jpg)

<br>